Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in pharma and consultancy business.[1]
- Market Cap ₹ 8.53 Cr.
- Current Price ₹ 8.45
- High / Low ₹ 14.6 / 7.50
- Stock P/E
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE -4.67 %
- ROE 1.16 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.45 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.18% over past five years.
- Promoter holding is low: 16.4%
- Company has a low return on equity of 3.66% over last 3 years.
- Working capital days have increased from 115 days to 247 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 13.94 | |
| 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 24.15 | |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -10.21 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -73.24% |
| 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 0.92 | |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.51 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -9.80 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | |
| 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -8.06 | |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -7.98 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -53% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -72% |
| TTM: | -3604% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -25% |
| 3 Years: | -26% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 4% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 | 9.04 |
| 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | 0.43 | |
| 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | 4.19 | |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
| 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 | 2.67 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 | 0.00 |
| 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 | 21.09 | |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | 4.85 | -9.82 | |
| 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | -1.79 | 3.07 | |
| 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | -1.17 | 0.24 | |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 | 1.90 | -6.51 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% |
Documents
Announcements
- Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025. 12 Feb
-
Board Meeting Outcome for Outcome For Board Meeting Held On 12.02.2026
12 Feb - Approved unaudited standalone and consolidated results for quarter and nine months ended 31 Dec 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
12 Feb - Appointed Dalavath Amar Singh (DIN:02206249) as Whole-Time Director; EGM Feb 12, 2026; 237,806 votes (100%) in favour.
- Shareholder Meeting / Postal Ballot-Outcome of EGM 12 Feb
-
Board Meeting Intimation for Meeting To Be Held On Thursday, 12Th February, 2026.
9 Feb - Board meeting on 12 Feb 2026 to consider unaudited Q3/9M results and limited review.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
DCL is in the business of:
a) Pharma:
Manufacturing and trading of Pharmaceutical products
b) Consultancy:
It also provides consultancy services